OncoSec Medical Inc (ONCSQ)

[chickpea598]

IL-12 will be in the headlines more as we move ahead into the future of oncology. Inovio's work with IL-12 will draw more attention to Oncosec and what they are doing with IL-12. Melanoma is just Oncosec's foot in the door with Merck. I think TNBC will eventually be put into a combo study with pembro and ep-IL12. Merck currently has a TNBC combo study with pembro and chemo. I can imagine that the 70% non-responders to pembro in that trial may just be looking for another alternative therapy such as Oncosec's ep-IL12 with pembro. I only hope that when we get some good interim results from the new Oncosec pembro-combo study, the market reacts in a positive way with regards to the share price. The expansion possibilities with regards to the non-responder (pembro) patient population for Merck would be big.....TNBC, head and neck, NSCLC, bladder. Keytruda (pembro) just keeps rolling along with more FDA approvals. Imagine a combo study with Oncosec for each one of these indications in the future. If Oncosec gets an FDA approval in this new registration combo study with pembro that will validate the therapy and Oncosec should be revalued at a way higher share price. Just my opinion of course.